Table 1 Clinical characteristics and EHPX1 methylation in the 25 patients with CBZ-resistant epilepsy
ID No. | Gender | Age | Final-dose (mg) | CBZ-concentration in blood (ug/ml) | CBZ-concentration / Final dose (Ratio) | Seizure-frequency | Course of disease (year) | EHPX1 methylation |
|---|---|---|---|---|---|---|---|---|
1 | M | 40 | 1000 | 5.6 | 5.6/1000 | 2/week(96/year) | 7 | 25% |
2 | F | 43 | 1000 | 6.5 | 6.5/1000 | 3/week(144/year) | 11 | 29% |
3 | F | 47 | 1000 | 4.8 | 4.8/1000 | 3.5/week(168/year) | 4 | 31% |
4 | M | 38 | 1000 | 5.2 | 5.2/1000 | 3/week(144/year) | 8 | 30% |
5 | F | 40 | 1000 | 6.7 | 6.7/1000 | 2/week(96/year) | 7 | 22% |
6 | M | 39 | 1000 | 7.2 | 7.2/1000 | 1.5/week(72/year) | 4 | 21% |
7 | F | 43 | 1200 | 6.8 | 5.7/1000 | 5/week(240/year) | 3 | 54% |
8 | M | 51 | 1000 | 7.6 | 7.6/1000 | 4/week(192/year) | 5 | 33% |
9 | F | 55 | 1200 | 6.2 | 5.1/1000 | 3.5/week(168/year) | 10 | 53% |
10 | F | 38 | 1000 | 8.1 | 8.1/1000 | 3/week(144/year) | 6 | 26% |
11 | F | 40 | 1000 | 7.3 | 7.3/1000 | 4/week(192/year) | 3 | 31% |
12 | F | 42 | 1000 | 6.6 | 6.6/1000 | 2.5/week(120/year) | 4 | 24% |
13 | M | 51 | 1200 | 7.2 | 6.0/1000 | 4.5/week(216/year) | 7 | 48% |
14 | F | 37 | 1000 | 6.5 | 6.5/1000 | 3/week(144/year) | 6 | 41% |
15 | M | 45 | 1000 | 6.1 | 6.1/1000 | 2.5/week(120/year) | 4 | 51% |
16 | M | 41 | 1000 | 7.2 | 7.2/1000 | 3/week(144/year) | 6 | 30% |
17 | M | 37 | 1200 | 4.7 | 3.9/1000 | 3.5/week(168/year) | 5 | 50% |
18 | F | 40 | 1000 | 7.7 | 7.7/1000 | 3/week(144/year) | 2 | 30% |
19 | F | 35 | 1000 | 8.4 | 8.4/1000 | 4/week(192/year) | 3 | 26% |
20 | F | 36 | 1000 | 7.8 | 7.8/1000 | 4/week(192/year) | 6 | 38% |
21 | F | 40 | 1000 | 8.9 | 8.9/1000 | 3/week(144/year) | 9 | 24% |
22 | M | 47 | 1200 | 9.2 | 7.6/1000 | 4.5/week(216/year) | 17 | 26% |
23 | M | 50 | 1000 | 6.9 | 6.9/1000 | 3/week(144/year) | 12 | 46% |
24 | F | 46 | 1000 | 6.4 | 6.4/1000 | 4/week(192/year) | 11 | 48% |
25 | M | 32 | 1000 | 5.8 | 5.8/1000 | 4/week(192/year) | 8 | 57% |